Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.9 USD | -0.97% | +1.05% | +0.35% |
Feb. 12 | Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
Feb. 07 | Craig-Hallum Initiates Acasti Pharma With Buy Rating, $6 Price Target | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 37.31M 27.28M |
---|---|---|---|---|---|
Net income 2024 * | -18M -13.16M | Net income 2025 * | -23M -16.81M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.05
x | P/E ratio 2025 * |
-2.64
x | Employees | 32 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.98% |
Latest transcript on Acasti Pharma Inc.
1 day | -0.97% | ||
1 week | +1.05% | ||
Current month | -15.33% | ||
1 month | -14.71% | ||
3 months | +13.73% | ||
6 months | +19.34% | ||
Current year | +0.35% |
Managers | Title | Age | Since |
---|---|---|---|
Prashant Kohli
CEO | Chief Executive Officer | 52 | 21-07-31 |
Director of Finance/CFO | 52 | Jan. 04 | |
Carrie D'Andrea
CTO | Chief Tech/Sci/R&D Officer | 52 | 23-05-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
A. Davis
BRD | Director/Board Member | 57 | 23-10-09 |
Director/Board Member | - | 23-10-09 | |
Santosh Kottayil
BRD | Director/Board Member | - | 23-10-09 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 2.9 | -0.97% | 3,831 |
24-04-25 | 2.928 | +0.98% | 2,583 |
24-04-24 | 2.9 | +0.69% | 8,424 |
24-04-23 | 2.88 | +1.05% | 4,480 |
24-04-22 | 2.85 | -0.70% | 9,896 |
Delayed Quote Nasdaq, April 26, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.35% | 27.26M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- ACST Stock